Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of MigraineMarch 11, 2019 7:30 AM Appaloosa Issues Statement Regarding Allergan's (AGN) Failed Anti-Depression Study, Seeks Independent ChairmanMarch 7, 2019 10:56 AM Appaloosa Issues Statement Regarding Allergan’s Failed Anti-Depression StudyMarch 7, 2019 10:55 AM Pre-Open Stock Movers 03/07: (ARQL) (ALSK) (GWRE) Higher; (APVO) (BPI) (KR) Lower (more...)March 7, 2019 9:26 AM Allergan (AGN) PT Cut To $189 At Wells Fargo After Rapastinel Misses EndpointsMarch 7, 2019 8:55 AM Allergen (AGN) PT Lowered to $155 at Credit SuisseMarch 7, 2019 8:04 AM Allergan (AGN) Says FDA Accepts sBLAs for BOTOX for Pediatric Patients with Upper and Lower Limb SpasticityMarch 7, 2019 8:02 AM Allergen (AGN) PT Lowered to $189 at Wells FargoMarch 7, 2019 7:16 AM Allergen (AGN) PT Lowered to $197 at BofA/Merrill LynchMarch 7, 2019 6:56 AM Allergen (AGN) PT Lowered to $174 at UBSMarch 7, 2019 6:03 AM Allergen (AGN) PT Lowered to $217 at SVB LeerinkMarch 7, 2019 3:27 AM